300430 Beijing Chieftain Control Engineering Technology
- 14.70
- +0.30+2.08%
Beijing Chieftain Control Engineering Technology News
Chengyitong (300430.SZ): The core product automated biological fermentation control system has many applications in the field of synthetic biology
Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Are there synthetic biological-related technologies currently being developed by the company?” The company replied that downstream customers in the company's intelligent manufacturing sector mainly include pharmaceutical and biological manufacturing companies. Biomaneling is mainly a production method using synthetic biotechnology as an important technical support and biological fermentation process as an important means of implementation. The company's core product, the automated biological fermentation control system, has many applications in the field of synthetic biology. Driven by synthetic biotechnology and green biological manufacturing, 202
Chengyitong (300430.SZ): Currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of invasive technology
Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Can the brain-computer products the company is developing regenerate insulin to treat diabetes?” The company replied that currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of intrusive technology. In planning non-invasive technology, the company integrates existing rehabilitation products with brain-computer interfaces to achieve product upgrades, thereby providing more effective rehabilitation services for patients with neurological diseases. In the future, the company will also focus on the application of brain-computer interfaces in other medical fields
Express News | Chengyitong: The company's core product, the automated biological fermentation control system, has many applications in the field of synthetic biology
Chengyitong (300430): Combining Internal and External Construction and Consolidation of Intelligent Manufacturing Brain-Computer Interfaces to Empower Rehabilitation Medicine
Incident: The company released its 2024 annual report and quarterly report. The company achieved operating income of 1,176 billion yuan (+20.63%) in 2023; net profit attributable to shareholders of listed companies was 170 million yuan (+36.
Chengyitong (300430.SZ) announced first-quarter results, net profit of 307.813 million yuan, an increase of 37.71%
Chengyitong (300430.SZ) released its report for the first quarter of 2024, achieving 2.68 operating income during the reporting period...
Dongfang Wealth Securities released a research report on April 24 stating that Chengyitong (300430.SZ) was given an increase in holdings rating. The main reasons for the rating include: 1) intelligent manufacturing: “internal and external development” pro
Dongfang Wealth Securities released a research report on April 24 stating that Chengyitong (300430.SZ) was given an increase in holdings rating. The main reasons for the rating include: 1) intelligent manufacturing: “internal and external development” promotes development, and project operation efficiency has improved markedly; 2) rehabilitation medicine: a deep focus on “brain-computer interface”, and the rural division is progressing steadily; 3) R&D investment has been further increased to enable pharmaceutical production; 4) the cost level has decreased slightly and profitability has increased. (Mainichi Keizai Shimbun)
Chengyitong (300430): Intelligent manufacturing and rehabilitation medicine go hand in hand to continuously improve profitability
Incident: The company released its annual report in 2012, achieved operating income of 1,176 billion yuan (yoy +21%) in 2023, achieved net profit of 170 million yuan (yoy +36%), and net profit of 1.49 million yuan (yoy +36%).
Chengyitong (300430.SZ) issued 2023 annual results, with net profit of 170 million yuan, an increase of 36.30% over the previous year
Chengyitong (300430.SZ) released its 2023 annual report. The company achieved operating income of 11 during the reporting period...
Chengyitong (300430.SZ): Long Zhijie has now developed products such as transcranial magnetic navigation systems and magnetic brain stimulation therapy devices
Gelonghui, April 12, 丨 Chengyitong (300430.SZ) said on the investor interactive platform that the company has always attached great importance to technical reserves and product development in brain science. The rehabilitation industry is one of the most successful and extensive fields of application of related technology. Long Zhijie began exploring related technologies in 2020. Currently, it has developed products such as transcranial magnetic navigation systems and magnetic brain stimulation therapy devices, and established Beijing Brain Link Technology Co., Ltd. on March 28, 2024. In the future, it will rely on Brain Connect Technology's platform to further explore brain-computer interface related technology and carry out related technical research and product development work, for big
Chengyitong (300430.SZ): Will rely on BrainLink Technology's platform to explore brain-computer interface-related technologies in depth
Gelonghui, April 8, 丨 Chengyitong (300430.SZ) said on the interactive platform that the company established Beijing Brain Connect Technology Co., Ltd. on March 28, 2024. The company will rely on BrainConnect Technology's platform to thoroughly explore brain-computer interface-related technologies, first using Longzhijie's existing products to achieve non-invasive brain function upgrades, and support R&D teams to explore invasive brain-computer technology research and development. The company will continue to cooperate deeply with senior teams from well-known universities to actively explore the application of brain science in the field of rehabilitation and medicine.
Musk's brain-computer interface company has made further progress. Neuralink is expected to open up a new market for large EEG models, and institutions are optimistic about laying out companies related to EEG models
① The global BCI market will reach 1.98 billion US dollars in 2023, and is expected to reach 3.3 billion US dollars by 2027, with a compound annual growth rate of about 14%; ② As the AI multi-modal model represented by the Sora model enters rapid development, brain-computer interfaces will continue to empower multi-modal related training, and Neuralink is expected to open up a new market for large EEG models.
The A-share brain-computer interface concept continues to decline
Gelonghui March 22 | Chengyitong fell nearly 6%, followed by Nanjing Panda, Boji Healthcare, Innovative Healthcare, and Sanbo Neurology.
Express News | Chengyitong: Controlling shareholders and actual controllers promise not to reduce their holdings within 12 months
Express News | Chengyitong: The company has become the governing unit of the Brain-Computer Interface Industry Alliance
Chengyitong (300430): Rehabilitation equipment deepens the intelligent vertical and horizontal development of primary medicine
Investment Summary The two major sectors went hand in hand, and the company's performance growth rate in the first three quarters of 2023 was impressive. The company was founded in 2003, landed on GEM in 2015, and expanded its business to rehabilitation medical facilities through the merger and acquisition of Longzhijie in 2017
Chengyitong (300430.SZ): Xinting Zhizhen's shareholding ratio fell below 5%
Gelonghui, Feb. 23, 丨 Chengyitong (300430.SZ) announced that the company recently received the “Simplified Equity Change Report” issued by Xinting Zhizhen and learned that Xinting Zhizhen reduced its holdings of the company's shares by 5,254,500 shares through bulk transactions on the Shenzhen Stock Exchange. After this transaction, Xinting Zhizhen's share holding ratio was reduced from 6.923404% to 4.999976%. It is no longer a shareholder holding more than 5% of the company's shares.
Chengyitong (300430.SZ): Controlling shareholders pledge an additional 4.5 million shares
Gelonghui, Feb. 8, 丨 Chengyitong (300430.SZ) announced that the company recently received a notice from Beijing Liwei Investment Co., Ltd. (“Liwei”), the controlling shareholder of the company, and learned that the company's shares held by it have applied for supplementary equity pledge business. The number of shares pledged this time is 4.5 million shares.
Express News | Chengyitong: Expected net profit to mother of 146 million yuan to 187 million yuan in 2023, an increase of 17.07%-49.94% year-on-year
Chengyitong (300430.SZ): Net profit is expected to increase 17.07%-49.94% year-on-year in 2023
On February 6, Gelonghui | Chengyitong (300430.SZ) announced that net profit for 2023 is estimated to be 146 million yuan to 187 million yuan, up 17.07%-49.94% from the same period last year, after deducting non-net profit of 121 million yuan to 162 million yuan, an increase of 6.40%-42.45% over the same period last year. In the intelligent manufacturing sector, the company continues to expand its business in the fields of chemical synthesis, traditional Chinese medicine and plant extraction, powder preparation, and intelligent packaging based on intelligent manufacturing in the field of biofermentation, and its advantageous business, while vigorously developing and innovating, along with new products such as “online near-infrared spectrometers”
Liweite, the controlling shareholder of Chengyitong (300430.SZ), and Leung Hok-yin, the actual controller, released the pledge of 19841,300 shares
Chengyitong (300430.SZ) announced that the company received Beijing Liweite Investment Co., Ltd., the controlling shareholder of the company (...
Analysis
Price Target
No Data
